RxDoctor Payments Data

Syed Mumtaz, MD

Child & Adolescent Psychiatry · Fort Wayne, INNPI 1396718573

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 51.7% of the total. Reporting peaked in 2020 at $235 and has fallen 83.2% since, to $40 in 2024.

$646in general payments, 2019–2025

Across 43 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$334
  • Ironshore Pharmaceuticals Inc.$84
  • AbbVie$57
  • Johnson & Johnson$43
  • Alkermes, Inc.$25
  • Otsuka America Pharmaceutical, Inc.$19
  • plus $84 from 6 others

What the payments were for

  • Food & beverage$646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$646 in reported general payments places this provider in the 60th percentile of 56 child & adolescent psychiatry providers in Indiana.

See all child & adolescent psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$15,408
Medicare patients
36
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$34,239
Olanzapine OdtOlanzapine12$4,543
Aripiprazole29$2,266
Vilazodone Hcl33$1,965
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$1,682
Buspirone Hcl82$1,228
Venlafaxine Hcl ErVenlafaxine Hcl106$1,164
Hydroxyzine Hcl41$996
Bupropion XlBupropion Hcl49$889
Trazodone Hcl97$829
Quetiapine Fumarate39$720
Clonazepam55$446
Oxcarbazepine14$420
Fluoxetine Hcl21$412
Prazosin Hcl19$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$19$34,23924 claims
Almatica Pharma LLCSertraline Hcl$18$22268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 56 child & adolescent psychiatry providers in Indiana.

Other child & adolescent psychiatry in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →